Panacea Biotec gains 5% on successful dengue vaccine trial

Internet Desk | Updated on September 24, 2020 Published on September 24, 2020

Panacea Biotec on Thursday announced the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAlI, a single-dose live-attenuated tetravalent vaccine.

According to the World Health Organization, Dengue represents one of the ten biggest global health threats, and we must have access to a safe and effective vaccine candidate that can reduce the devastating impact of Dengue fever in endemic regions.

The shares are trading at a day's high of Rs 198.15, rising up to 4.98 per cent.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on September 24, 2020
This article is closed for comments.
Please Email the Editor